Treatment of Midgut Neuroendocrine Tumors

Video

This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.

In this video, Jonathan Strosberg, MD, of the Moffitt Cancer Center, discusses current options for the treatment of midgut neuroendocrine tumors; highlights results of the NETTER-1 trial, which showed improved progression-free survival with lutetium-177 (177Lu)–Dotatate in this patient population; and discusses the use of radionuclide therapy in other types of neuroendocrine tumors.

Results of the phase III NETTER-1 trial were recently published in the New England Journal of Medicine, showing that treatment of well-differentiated, metastatic midgut neuroendocrine tumors with 177Lu–Dotatate improved response rates (18% vs 3%) and improved the estimated rate of progression-free survival at 20 months (65.2% vs 10.8%).

Dr. Strosberg spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held last month in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content